DOI QR코드

DOI QR Code

Association of PINX1 but not TEP1 Polymorphisms with Progression to Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B Virus Infection

  • Sriprapun, Methee (Research Unit of Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University) ;
  • Chuaypen, Natthaya (Research Unit of Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University) ;
  • Khlaiphuengsin, Apichaya (Research Unit of Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University) ;
  • Pinjaroen, Nutcha (Department of Radiology, Faculty of Medicine, Chulalongkorn University) ;
  • Payungporn, Sunchai (Research Unit of Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University) ;
  • Tangkijvanich, Pisit (Research Unit of Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University)
  • Published : 2016.06.01

Abstract

Hepatocellular carcinoma (HCC) is major health problem with high mortality rates, especially in patients with hepatitis B virus (HBV) infection. Telomerase function is one of common mechanisms affecting genome stability and cancer development. Recent studies demonstrated that genetic polymorphisms of telomerase associated genes such as telomerase associated protein 1 (TEP1) rs1713449 and PIN2/TERF1-interacting telomerase inhibitor 1 (PINX1) rs1469557 may be associated with risk of HCC and other cancers. In this study, 325 patients with HCC and 539 non-HCC groups [193 healthy controls, 80 patients with HBV-related liver cirrhosis (LC) and 266 patients with HBV-related chronic hepatitis (CH)] were enrolled to explore genetic polymorphisms of both SNPs using the allelic discrimination method based on MGB probe TaqMan real time PCR. We demonstrated that all genotypes of both genes were in Hardy-Wienberg equilibrium (P>0.05). Moreover, there was no significant association between rs1713449 genotypes and HCC risk, HCC progression and overall survival (P>0.05). Interestingly, we observed positive association of rs1469557 with risk of HCC when compared with the LC group under dominant (CC versus CT+TT, OR=1.89, 95% CI= 1.06-3.40, P=0.031) and allelic (C versus T alleles, OR=1.75, 95% CI=1.04-2.94, P=0.033) models, respectively. Moreover, overall survival of HCC patients with CC genotype of rs1469557 was significantly higher than non-CC genotype (Log-rank P=0.015). These findings suggest that PINX1 rs1469557 but not TEP1 rs1469557 might play a role in HCC progression in Thai patients with LC and be used as the prognosis marker to predict overall survival in HCC patients.

Keywords

TEP1;PINX1;hepatocellular carcinoma;chronic hepatitis B virus;telomerase;polymorphism

Acknowledgement

Supported by : Chulalongkorn University

References

  1. Becker SA, Zhou YZ, Slagle BL (1996). Frequent loss of chromosome 8p in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res, 56, 5092-7.
  2. Bruix J, Sherman M (2005). Diagnosis of Small HCC. Gastroenterol, 129, 1364. https://doi.org/10.1053/j.gastro.2005.08.046
  3. Cai MY, Zhang B, He WP, et al (2010). Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci, 101, 1543-9. https://doi.org/10.1111/j.1349-7006.2010.01560.x
  4. Chang J, Dinney CP, Huang M, et al (2012). Genetic variants in telomere-maintenance genes and bladder cancer risk. PLoS One, 7, 30665. https://doi.org/10.1371/journal.pone.0030665
  5. Chanthra N, Payungporn S, Chuaypen N, et al (2015). Association of Single Nucleotide Polymorphism rs1053004 in Signal Transducer and Activator of Transcription 3 (STAT3) with Susceptibility to Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B. Asian Pac J Cancer Prev, 16, 5069-73. https://doi.org/10.7314/APJCP.2015.16.12.5069
  6. Chemin I, Zoulim F (2009). Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett, 286, 52-9. https://doi.org/10.1016/j.canlet.2008.12.003
  7. Cong YS, Wright WE, Shay JW (2002). Human telomerase and its regulation. Microbiol Mol Biol Rev, 66, 407-25, table of contents. https://doi.org/10.1128/MMBR.66.3.407-425.2002
  8. Gu C, Li Q, Zhu Y, et al (2015). Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. Prostate Cancer Prostatic Dis, 18, 310-6. https://doi.org/10.1038/pcan.2015.27
  9. Hartmann D, Srivastava U, Thaler M, et al (2011). Telomerase gene mutations are associated with cirrhosis formation. Hepatol, 53, 1608-17. https://doi.org/10.1002/hep.24217
  10. Jung SW, Park NH, Shin JW, et al (2014). Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B. Hepatol, 59, 1912-20. https://doi.org/10.1002/hep.26655
  11. Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38. https://doi.org/10.1055/s-2007-1007122
  12. Shi M, Cao M, Song J, et al (2015). PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NFkappaB/MMP-9 signaling pathway. Mol Cancer, 14, 66. https://doi.org/10.1186/s12943-015-0332-2
  13. Somboon K, Siramolpiwat S, Vilaichone RK (2014). Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand. Asian Pac J Cancer Prev, 15, 3567-70. https://doi.org/10.7314/APJCP.2014.15.8.3567
  14. Varadi V, Brendle A, Brandt A, et al (2009). Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis. Eur J Cancer, 45, 3008-16. https://doi.org/10.1016/j.ejca.2009.08.012
  15. Yan L, Wu S, Zhang S, et al (2014). Genetic variants in telomerase reverse transcriptase (TERT) and telomeraseassociated protein 1 (TEP1) and the risk of male infertility. Gene, 534, 139-43. https://doi.org/10.1016/j.gene.2013.11.008
  16. Zhou XZ (2011). PinX1: a sought-after major tumor suppressor at human chromosome 8p23. Oncotarget, 2, 810-9. https://doi.org/10.18632/oncotarget.339